Gans, Hayley http://orcid.org/0000-0001-9190-263X
Chemaly, Roy F. http://orcid.org/0000-0002-0277-3088
Funding for this research was provided by:
Cangene Corporation
Saol Therapeutics
Article History
Received: 18 June 2020
Accepted: 24 November 2020
First Online: 11 January 2021
Ethics approval and consent to participate
: This study was conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation, the Declaration of Helsinki, and all applicable federal and local regulations and institutional review board guidelines. The protocol and amendments, the informed consent form, and study-related materials were reviewed and approved by a central independent ethics committee (Western Institutional Review Board, Puyallup, WA, USA) before study initiation and throughout the conduct of the study. All patients (or their guardians) provided written informed consent.
: Not applicable.
: HG has received funding/grant support from National Vaccine Program Office, National Institutes of Health, and honorarium for consultancy from US Department of Health and Human Services. RFC has received funding/grant support paid to his institution from Merck, Chimerix, Viracor, Oxford Immunotec, Xenex, Gilead, Ansun Pharmaceuticals, Shire/Takeda, and AiCuris, and honorarium for consultancy from Xenex, Merck, Chimerix, Shire/Takeda, Ansun Pharmaceuticals, Pulmotec, Clinigen, Oxford Immunotec, ReViral, Kyorin, Genentech, and Janssen.